Navigation Links
AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder
Date:1/7/2009

er was granted Conformite Europeenne (CE) Mark in Europe in February 1998 and U.S. Food and Drug Administration (FDA) approval in May 2003. AGA Medical's second generation AMPLATZER Duct Occluder - ADO II - has been granted CE Mark approval in Europe and can be delivered through even smaller catheters and is appropriate for both smaller ducts and ducts with different geometries. AGA Medical has a clinical trial underway to support approval for the ADO II in the United States.

About Patent Ductus Arteriosus

The ductus arteriosus is an open channel in every fetus that allows blood to bypass the lungs, which are not used until the baby takes its first breath after birth. Shortly after the baby's first breath, the ductus arteriosus should close permanently. If it does not close, it is known as a PDA. This condition can cause symptoms such as fatigue, difficulty or rapid breathing, failure to grow normally, or chronic respiratory infections such as colds and pneumonia, or endocarditis. PDA can also be asymptomatic. Large openings can lead to heart failure and death.

About AGA Medical

AGA Medical, based in Plymouth, Minnesota, is a leader in developing interventional devices for the minimally invasive treatment of cardiovascular defects and peripheral vascular disease. Founded in 1995 by Dr. Kurt Amplatz, a former professor and researcher at the University of Minnesota Department of Radiology, AGA Medical develops and commercializes devices for a range of structural heart repair and circulatory conditions. Several of these devices have been major innovations in the treatment of the most common congenital "holes in the heart," such as atrial septal defects, patent ductus arteriosis, and patent foramen ovales.

More than 700 articles have been published in medical literature that support the benefits of AGA Medical devices, including improved patient outcomes, reduced
'/>"/>

SOURCE AGA Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... today launches the Knowledge & Resource Center, a collection ... care transitions and positively impact health outcomes. , By ... tools or resources that align with its mission to ... the promotion of public policy, and education and focused ... Knowledge & Resource Center serves as a mechanism by ...
(Date:4/1/2015)... LINCOLN, R.I. (PRWEB) April 01, 2015 After ... potholes. Driving over these potholes can lead to costly damage, ... your vehicle. , Amica is sharing the following suggestions from ... have plenty of tread and be inflated to the manufacturer’s ... change in vehicle handling, excessive vibration and uneven tire wear ...
(Date:4/1/2015)... April 01, 2015 The Pennsylvania Court ... lawsuits ( http://www.risperdallawsuit2014.com/ ) has scheduled a meeting ... the Philadelphia Court of Common Pleas, the meeting will ... Hall. Court records indicate that the proceeding will address ... of Risperdal users who experienced gynecomastia (male breast growth) ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
(Date:4/1/2015)... Manistee, Michigan (PRWEB) April 01, 2015 ... visit Best Drug Rehabilitation’s blog, where the latest post ... of last month’s observation of Teen Dating Violence Awareness ... toolkit on this growing problem to help parents identify ... their romantic interest that might involve drugs or alcohol. ...
Breaking Medicine News(10 mins):Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... for female clinicians, including intelligent innovations that redefine the way women ... and first-of-their-kind enhancements, Medelita sets a new standard for quality, comfort, ... the U.S. alone wearing scrubs and lab coats to work. ... ...
... 12 Former Speaker of the,House and Founder of the ... hearing of the passing of Tony Snow:, "With the ... loving,father, and a very talented journalist., "Tony was at ... knowledge,of politics and government had been greatly expanded by his ...
... tumor suppressor instead , , FRIDAY, July 11 (HealthDay News) -- ... cancer cells in lab cultures was, until recently, thought to ... have found that a gene called TCF7L2 is active in ... malfunction in a gene. As a result, researchers suspected TCF7L2 ...
... President Sirleaf while part of Mercy Ships Crew , ... ... from a week-long international humanitarian mission to support Mercy Ships, his ... training camp with an additional sense of purpose knowing that he's ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader in ... and imaging facilities,announced today that the Strategic Alternatives ... and Company as Lead Advisor and SunTrust,Robinson Humphrey ... evaluates all,strategic options available to the company., ...
... July 11 In a letter to the,Senate, ... policymakers to address critical shortfalls in legislation that ... With the Senate,poised to vote on a five-year, ... policymakers to "both set and correct policies based,on ...
Cached Medicine News:Health News:Medelita Introduces A Breakthrough In Healthcare Uniforms For Women 2Health News:Medelita Introduces A Breakthrough In Healthcare Uniforms For Women 3Health News:Newt Gingrich Statement on the Loss of Tony Snow 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 2Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 4Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 5
(Date:4/1/2015)... 1, 2015 Trinity Biotech plc (Nasdaq: ... of diagnostic products for the point-of-care and clinical ... Limited, its wholly-owned subsidiary (the "Issuer"), intends to ... million aggregate principal amount of Exchangeable Senior Notes ... institutional buyers pursuant to Rule 144A under the ...
(Date:4/1/2015)... 1, 2015  Pittman Motors has significantly expanded ... PLG42K, PLG42S, PLG52, and PLG63 planetary gearboxes. These ... brushless DC motors and complement Pittman,s existing spur ... 35 standard motor-gearbox family combinations to the Pittman ... high torque loads with excellent efficiency and are ...
(Date:4/1/2015)... MOUNTAIN VIEW, Calif. , April 1, ... ) announces that it has signed a definitive ... device company that develops, manufactures and sells minimally ... drainage of targeted areas within the gastrointestinal tract. ... The Xlumena portfolio includes the ...
Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
... monitors and controls patient temperature primarily in ... surgery, trauma, or other medical conditions. The ... provided from a patient temperature probe. Circulating ... and 42C (107.6F) to achieve a preset ...
... The Littmann Electronic Stethoscope Model 4100WS ... (ANR) technology allowing you to reduce ambient ... without eliminating critical body sounds. Three frequency ... lung, and other body sounds: Bell (20-200 ...
... The OmniMD orthopedics EMR addresses the vast ... specific EMR includes clinically-defined templates for common ... review of systems. The system also includes ... are used to capture accurate charges and ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
Medicine Products: